Evidence map›Paper›PMID 24093841›Full record

ReviewAmerican heart journal2013

Learning from recent trials and shaping the future of acute heart failure trials.

Robert J Mentz, Gary Michael Felker, Tariq Ahmad, William Frank Peacock, Bertram Pitt, Mona Fiuzat, Aldo P Maggioni, Mihai Gheorghiade, Yuki Ando, Stuart J Pocock and 2 more

Open access · greenAbstract readReview
In one paragraph

Review in American heart journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Hypertension and Heart Failure: From Pathophysiology to Treatment.International journal of molecular sciences · 2024
    Review
  4. Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023
    Review
  5. Phase II Trials in Drug Development and Adaptive Trial Design.JACC. Basic to translational science · 2019
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Arrhythmogenic right ventricular dysplasia back in force.The American journal of cardiology · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Robert J MentzDuke University, Durham, NC. Electronic address: robert.mentz@duke.edu.
Gary Michael Felker
Tariq Ahmad
William Frank Peacock
Bertram Pitt
Mona Fiuzat
Aldo P Maggioni
Mihai Gheorghiade
Yuki Ando
Stuart J Pocock
Faiez Zannad
Christopher M O'Connor
Duke University · USAssociazione Nazionale Medici Cardiologi Ospedalieri · ITBaylor College of Medicine · USNorthwestern University · USPharmaceuticals and Medical Devices Agency · JPUniversity of London · GBUniversity of Michigan–Ann Arbor · US

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine. As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF. Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites. We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials. This review is based on discussions between scientists, clinical trialists, and regulatory representatives at the 9th Global Cardio Vascular Clinical Trialists Forum in Paris, France, from November 30 to December 1, 2012.

Indexed as

Disease ManagementForecastingAcute DiseaseClinical Trials as TopicHeart FailureHumans

Identifiers

PMID24093841
PMCPMC3906624
OpenAlexW2050044847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.